Molecular therapy for TIIDM and Metabolic defects: Syringic acid increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 28/November/2017, 11.43 pm

Amino acid-based therapy for TIIDM and obesity-associated metabolic deficits: D-Serine increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 28/February/2018, 11.32 pm
February 28, 2018
Combinatorial therapy for Deafness: A therapeutic mix encompassing Spermidine, Cholecalciferol, Ajoene and DIM (SCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 28/February/2018, 11.55 pm
February 28, 2018
Show all

National Science day special

*********

We wish everyone a very happy national science day. On this special occasion, we are happy to announce that Bio-Med/Pharma ideas posted today (28/February/2018) will be available to the use of Scientists/Professors/Teachers/Physicians/Researchers for free. So, there will be no terms and conditions for the ideas posted today. Each idea posted will be served first come, first serve basis. Write to admin@genomediscovery.org for more details.

Dr L Boominathan PhD

President, Director & CSO, GBMD.

___________________________________________________________________________________________________________________________

 

Introduction: What they say

A study from the “Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27701, USA; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Durham, NC 27710, USA” shows that “SIRT4 Is a Lysine Deacylase that Controls Leucine Metabolism and Insulin Secretion.” This research paper was published, in the 4 April 2017 issue of the journal “Cell Metabolism” [One of the best research journals in Metabolism with an I.F of 28 plus], by Prof. Hirschey MD and Anderson KA and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for TIIDM and Metabolic defects: Syringic acid increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


What is known?

Prof. Hirschey research team has recently shown that Loss of Sirtuin-4 in mice results in:(1) dysregulated leucine metabolism; (2) abnormal insulin secretion; (3) glucose intolerance; and (4) accelerated-age induced insulin resistance, suggesting that increasing the expression of Sirtuin-4 in diabetic and obese patients may alleviate TIIDM and metabolic defects.


From Research findings to Therapeutic opportunity:

This study suggests that Syringic acid may aid in the treatment of TIIDM and metabolic defects. Syringic acid, by increasing the expression of its target gene, it may increase the expression of Sirtuin-4. Thereby, it may: (1) normalize leucine metabolism; (2) promote insulin secretion; (3) promote glucose homeostasis during ageing; and (4) decrease metabolic stress (Fig.1).

Figure 1. Mechanistic insights into how Syringic acid functions as an antihyperglycemic agent. Syringic acid, by increasing the expression of Sirtuin-4, it may normalize leucine metabolism and promote insulin secretion.

Figure 2. The chemical structure of Syringic acid.

Thus, pharmacological formulations encompassing “Syringic acid or its analogues, either alone or in combination with other drugs” may be used to promote glucose homeostasis and treat TIIDM.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Syringic acid increase the expression of Sirtuin-4 to promote insulin secretion?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Molecular therapy for TIIDM and Metabolic defects: Syringic acid increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 28/November/2017, 11.42 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.